Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism

Gaetano Lombardi, Mauro Iodice, Paolo Miletto, Bartolomeo Merola, Nicola Panza, Lucio Annunziato

Research output: Contribution to journalArticlepeer-review


The effects of the dopamine (DA) receptor antagonist metoclopramide on the plasma thyroid stimulating hormone (TSH) and prolactin (PRL) levels were studied in 8 patients with subclinical hypothyroidism (defined as absence of clinical signs of hypothyroidism with normal thyroid hormone levels, normal or slightly increased basal plasma TSH levels and increased and long-lasting TSH response to TRH I before and after l-thyroxine replacement therapy. Metoclopramide induced a significant (p <0.01) TSH release in the subclinical hypothyroid patients. Two weeks after l-thyroxine replacement therapy (50 μg/day), the TSH response to metoclopramide was completely blunted in subclinical hypothyroidism. In these patients a significant (p <0.01) inhibition of TSH response to intravenous thyrotropin-releasing hormone (TRH) was also observed after treatment with thyroid hormone. In analogy to the TSH behavior, plasma PRL secretion in response to metoclopramide and TRH administration was significantly (p<0.05) inhibited in the subclinical hypothyroid patients after l-thyroxine replacement therapy.

Original languageEnglish
Pages (from-to)676-678
Number of pages3
Issue number6
Publication statusPublished - 1986


  • Metoclopramide
  • Prolactin
  • Subclinical hypothyroidism
  • Thyroid-stimulating hormone
  • Thyrotropin-releasing hormone

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems
  • Neuroscience(all)


Dive into the research topics of 'Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism'. Together they form a unique fingerprint.

Cite this